• 1
    Bosch FX, Lorincz A, Muñoz N, Meijer CJLM, Shah KV. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002; 55: 24465.
  • 2
    Bosch FX, Manos MM, Muñoz N, Sherman M, Jansen AM, Peto J, Schiffman MH, Moreno V, Kurman R, Shah KV. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective: international biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst 1995; 87: 796802.
  • 3
    Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Muñoz N. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189: 129.
  • 4
    Coursaget P, Muñoz N. Vaccination against infectious agents associated with human cancer. Cancer Surv 1999; 33: 35581.
  • 5
    Harro CD, Pang YY, Roden RB, Hildesheim A, Wang Z, Reynolds MJ, Mast TC, Robinson R, Murphy BR, Karron RA, Dillner J, Schiller JT, Lowy DR. Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. J Natl Cancer Inst 2001; 93: 28492.
  • 6
    Evans TG, Bonnez W, Rose RC, Koenig S, Demeter L, Suzich JA, O'Brien D, Campbell M, White WI, Balsley J, Reichman RC. A Phase 1 study of a recombinant viruslike particle vaccine against human papillomavirus type 11 in healthy adult volunteers. J Infect Dis 2001; 183: 148593.
  • 7
    Herrero R, Hildesheim A, Bratti C, Sherman ME, Hutchinson M, Morales J, Balmaceda I, Greenberg MD, Alfaro M, Burk RD, Wacholder S, Plummer M, et al. Population-based study of human papillomavirus infection and cervical neoplasia in rural Costa Rica. J Natl Cancer Inst 2000; 92: 46474.
  • 8
    Sellors JW, Mahony JB, Kaczorowski J, Lytwyn A, Bangura H, Chong S, Lorincz A, Dalby DM, Janjusevic V, Keller JL. Prevalence and predictors of human papillomavirus infection in women in Ontario, Canada. Survey of HPV in Ontario Women (SHOW) Group. CMAJ 2000; 163: 5038.
  • 9
    Lazcano-Ponce E, Herrero R, Muñoz N, Cruz A, Shah KV, Alonso P, Hernandez P, Salmeron J, Hernandez M. Epidemiology of HPV infection among Mexican women with normal cervical cytology. Int J Cancer 2001; 91: 41220.
  • 10
    Matos E, Loria D, Amestoy G, Herrera L, Prince MA, Muñoz N, Herrero R. A survey on smoking behaviour in relation to demographic, sexual and reproductive characteristics of women in Concordia, Argentina. J Prev Med 2002; in press.
  • 11
    Sukvirach S, Smith JS, Kesararat W, Kaenploy V, Meijer CJ, Snijders PJ, Franceschi S, Herrero R. Population-based human papillomavirus prevalence in Lampang and Songkla, Thailand. 19th International Papillomavirus Conference 2001;P-243:149.
  • 12
    Anh PTH, Hieu NT, Herrero R, Vaccarella S, Smith JS, Thuy NT, Nga NH, Duc NB, Ashley R, Snijders PJ, Meijer CJ, Muñoz N, Parkin DM, et al. Human papillomavirus infection among women in South and North Vietnam. Br J Cancer 2002; (in press).
  • 13
    Konya J, Dillner J. Immunity to oncogenic human papillomaviruses. Adv Cancer Res 2001; 82: 20538.
  • 14
    Combita AL, Bravo MM, Touze A, Orozco O, Coursaget P. Serologic response to human oncogenic papillomavirus types 16, 18, 31, 33, 39, 58 and 59 virus-like particles in Colombian women with invasive cervical cancer. Int J Cancer 2002; 97: 796803.
  • 15
    IARC. IARC Biennial Report 2000/2001. Lyon: International Agency for Research on Cancer, 2001.
  • 16
    Shin RH, Lee DH. Cancer Incidence in Busan, Korea, 1996–97. Busan: Association of Busan Cancer Registry, 2000.
  • 17
    Jacobs MV, Walboomers JM, Snijders PJ, Voorhorst FJ, Verheijen RH, Fransen-Daalmeijer N, Meijer CJ. Distribution of 37 mucosotropic HPV types in women with cytologically normal cervical smears: the age-related patterns for high-risk and low-risk types. Int J Cancer 2000; 87: 2217.
  • 18
    Walboomers JM, Melkert P, van den Brule AJ, Snijders PJ, Meijer CJ. The polymerase chain reaction for human papillomavirus screening in diagnostic cytopathology of the cervix. In: HerringtonOS, McGeeO (eds.), Diagnostic molecular pathology: a practical approach, pp. 152172, Oxford: Oxford University Press, 1992.
  • 19
    Jacobs MV, Roda Husman AM, van den Brule AJ, Snijders PJ, Meijer CJ, Walboomers JM. Group-specific differentiation between high- and low-risk human papillomavirus genotypes by general primer-mediated PCR and two cocktails of oligonucleotide probes. J Clin Microbiol 1995; 33: 9015.
  • 20
    Touzé A, de Sanjose S Coursaget P, Almirall MR, Palacio V, Meijer CJ, Kornegay J, Bosch FX. Prevalence of anti-human papillomavirus type 16, 18, 31, and 58 virus-like particles in women in the general population and in prostitutes. J Clin Microbiol 2001; 39: 43448.
  • 21
    Combita AL, Touze A, Bousarghin L, Christensen ND, Coursaget P. Identification of two cross-neutralizing linear epitopes within the L1 major capsid protein of human papillomavirus. J Virol 2002; 76: XXXX.
  • 22
    Ribes JA, Hayes M, Smith A, Winters JL, Baker DJ. Comparative performance of herpes simplex virus type 2-specific serologic assays from Meridian Diagnostics and MRL diagnostics. J Clin Microbiol 2001; 39: 37402.
  • 23
    Clifford GM, Smith JS, Plummer M, Muñoz N, Franceschi S. Human papillomavirus in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer in press.
  • 24
    Lin QQ, Yu SZ, Qu W, Cruz Y, Burk RD. Human papillomavirus types 52 and 58. Int J Cancer 1998; 75: 4845.
  • 25
    Molano M, Posso H, Weiderpass E, van den Brule AJ, Ronderos M, Franceschi S. Prevalence and determinants of HPV infection among Colombian women with normal cytology. Br J Cancer 2002; 87: 32433.
  • 26
    Ferlay J, Bray F, Pisani P, Parkin DM. Globocan 2000: incidence mortality and prevalence worldwide. [cd-rom], Lyon: International Agency for Research on Cancer. 2001.
  • 27
    Castellsague X, Menendez C, Loscertales MP, Kornegay JR, dos SF, Gomez-Olive FX, Lloveras B, Abarca N, Vaz N, Barreto A, Bosch FX, Alonso P. Human papillomavirus genotypes in rural Mozambique. Lancet 2001; 358: 142930.
  • 28
    Kjaer SK, van den Brule AJ, Bock JE, Poll PA, Engholm G, Sherman ME, Walboomers JM, Meijer CJ. Determinants for genital human papillomavirus (HPV) infection in 1000 randomly chosen young Danish women with normal Pap smear: are there different risk profiles for oncogenic and nononcogenic HPV types? Cancer Epidemiol Biomarkers Prev 1997; 6: 799805.
  • 29
    Muñoz N, Kato I, Bosch FX, Eluf-Neto J, de Sanjosé S, Ascunce N, Gili M, Izarzugaza I, Viladiu P, Tormo MJ, Moreo P, Gonzalez LC, et al. Risk factors for HPV DNA detection in middle-aged women. Sex Transm Dis 1996; 23: 50410.
  • 30
    Deacon JM, Evans CD, Yule R, Desai M, Binns W, Taylor C, Peto J. Sexual behaviour and smoking as determinants of cervical HPV infection and of CIN3 among those infected: a case-control study nested within the Manchester cohort. Br J Cancer 2000; 83: 156572.
  • 31
    Bosch FX, Castellsague X, Muñoz N, de Sanjosé S, Ghaffari AM, Gonzalez LC, Gili M, Izarzugaza I, Viladiu P, Navarro C, Vergara A, Ascunce N, et al. Male sexual behavior and human papillomavirus DNA: key risk factors for cervical cancer in Spain. J Natl Cancer Inst 1996; 88: 10607.
  • 32
    Sun Y, Eluf-Neto J, Bosch FX, Muñoz N, Walboomers JM, Meijer CJ, Shah KV, Clayman B, Viscidi RP. Serum antibodies to human papillomavirus 16 proteins in women from Brazil with invasive cervical carcinoma. Cancer Epidemiol Biomarkers Prev 1999; 8: 93540.
  • 33
    Carter JJ, Koutsky LA, Hughes JP, Lee SK, Kuypers J, Kiviat N, Galloway DA. Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection. J Infect Dis 2000; 181: 19119.
  • 34
    zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nature Rev Cancer 2002; 2: 34250.
  • 35
    Tindle RW. Immune evasion in human papillomavirus-associated cervical cancer. Nature Rev Cancer 2002; 2: 5965.
  • 36
    Hwang T. Detection and typing of human papillomavirus DNA by PCR using consensus primers in various cervical lesions of Korean women. J Korean Med Sci 1999; 14: 5939.
  • 37
    Kols A, Sherris J. HPV vaccines: promise and challenges. Seattle, WA, USA: PATH. 2000.